Jason J. Luke, MD
Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment, according to a presentation by Jason Luke, MD, at the 36th Annual CFS®
As single-agents, the immune checkpoint inhibitors have demonstrated utility across a broad spectrum of tumors. Additionally, some combinations of anti–PD-1 and anti–CTLA-4 inhibitors have gained approval along with immunotherapy and chemotherapy combinations. However, the recent failed phase III trial looking at pembrolizumab (Keytruda) and epacadostat has called research practices into question.
... to read the full story